<!DOCTYPE article
PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD with MathML3 v1.3 20210610//EN" "JATS-archivearticle1-3-mathml3.dtd">
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" dtd-version="1.3" xml:lang="en" article-type="abstract"><?properties open_access?><processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats"><restricted-by>pmc</restricted-by></processing-meta><front><journal-meta><journal-id journal-id-type="nlm-ta">Eur Psychiatry</journal-id><journal-id journal-id-type="iso-abbrev">Eur Psychiatry</journal-id><journal-id journal-id-type="publisher-id">EPA</journal-id><journal-title-group><journal-title>European Psychiatry</journal-title></journal-title-group><issn pub-type="ppub">0924-9338</issn><issn pub-type="epub">1778-3585</issn><publisher><publisher-name>Cambridge University Press</publisher-name><publisher-loc>Cambridge, UK</publisher-loc></publisher></journal-meta>
<article-meta><article-id pub-id-type="pmc">PMC11861569</article-id><article-id pub-id-type="doi">10.1192/j.eurpsy.2024.1540</article-id><article-id pub-id-type="other">EPV0950</article-id><article-id pub-id-type="pii">S0924933824015402</article-id><article-categories><subj-group subj-group-type="heading"><subject>Abstract</subject></subj-group><subj-group subj-group-type="section"><subject>e-Poster Viewing</subject></subj-group></article-categories><title-group><article-title>Prevalence of diabetes and insulin resistance in patients with diagnosis of schizophrenia or other psicotic disorders</article-title></title-group><contrib-group><contrib contrib-type="author" corresp="yes"><name><surname>Andres-Olivera</surname><given-names>P.</given-names></name><xref rid="aff3365" ref-type="aff">
<sup>1</sup>
</xref><xref rid="aff3366" ref-type="aff">
<sup>2</sup>
</xref><xref rid="aff3367" ref-type="aff">
<sup>3</sup>
</xref><xref rid="cor1389" ref-type="corresp">
<sup>*</sup>
</xref></contrib><contrib contrib-type="author"><name><surname>Seabra de Brito</surname><given-names>J.</given-names></name><xref rid="aff3366" ref-type="aff">
<sup>2</sup>
</xref></contrib><contrib contrib-type="author"><name><surname>Arribas-Simon</surname><given-names>B.</given-names></name><xref rid="aff3368" ref-type="aff">
<sup>4</sup>
</xref></contrib><contrib contrib-type="author"><name><surname>Martin-Gomez</surname><given-names>C.</given-names></name><xref rid="aff3365" ref-type="aff">
<sup>1</sup>
</xref><xref rid="aff3366" ref-type="aff">
<sup>2</sup>
</xref><xref rid="aff3367" ref-type="aff">
<sup>3</sup>
</xref></contrib><contrib contrib-type="author"><name><surname>Bote</surname><given-names>B.</given-names></name><xref rid="aff3365" ref-type="aff">
<sup>1</sup>
</xref><xref rid="aff3366" ref-type="aff">
<sup>2</sup>
</xref></contrib><contrib contrib-type="author"><name><surname>Payo</surname><given-names>C.</given-names></name><xref rid="aff3365" ref-type="aff">
<sup>1</sup>
</xref></contrib><contrib contrib-type="author"><name><surname>Munaiz</surname><given-names>C.</given-names></name><xref rid="aff3365" ref-type="aff">
<sup>1</sup>
</xref></contrib><contrib contrib-type="author"><name><surname>Brito</surname><given-names>R.</given-names></name><xref rid="aff3365" ref-type="aff">
<sup>1</sup>
</xref></contrib><contrib contrib-type="author"><name><surname>Ligero-Argudo</surname><given-names>M.</given-names></name><xref rid="aff3365" ref-type="aff">
<sup>1</sup>
</xref></contrib><contrib contrib-type="author"><name><surname>Jimenez Martinez</surname><given-names>D.</given-names></name><xref rid="aff3365" ref-type="aff">
<sup>1</sup>
</xref></contrib><contrib contrib-type="author"><name><surname>Roncero</surname><given-names>C.</given-names></name><xref rid="aff3365" ref-type="aff">
<sup>1</sup>
</xref><xref rid="aff3366" ref-type="aff">
<sup>2</sup>
</xref><xref rid="aff3369" ref-type="aff">
<sup>5</sup>
</xref></contrib></contrib-group><aff id="aff3365"><sup>1</sup>Psychiatric Service, <institution>University of Salamanca Health Complex</institution></aff><aff id="aff3366"><sup>2</sup>Psychiatric Unit. School of Medicine, <institution>University of Salamanca</institution></aff><aff id="aff3367"><sup>3</sup>PRINT, <institution>Biomedical Research Institute (IBSAL)</institution>, <city>Salamanca</city></aff><aff id="aff3368"><sup>4</sup>Psychiatric Service, <institution>University of Valladolid Healthcare Complex</institution>, <city>Valladolid</city></aff><aff id="aff3369"><sup>5</sup><institution>Biomedical Research Institute (IBSAL)</institution>, <city>Salamanca</city>, <country>Spain</country></aff><author-notes><corresp id="cor1389"><label>*</label>Corresponding author.</corresp></author-notes><pub-date publication-format="electronic" date-type="collection" iso-8601-date="2024-04"><month>4</month><year>2024</year></pub-date><pub-date pub-type="epub"><day>27</day><month>8</month><year>2024</year></pub-date><volume>67</volume><issue seq="1515">Suppl 1</issue><issue-title content-type="special_issue">Abstracts of the 32nd European Congress of Psychiatry</issue-title><fpage>S741</fpage><lpage>S741</lpage><permissions><copyright-statement>&#x000a9; The Author(s) 2024</copyright-statement><copyright-year>2024</copyright-year><copyright-holder>The Author(s)</copyright-holder><license><ali:license_ref xmlns:ali="http://www.niso.org/schemas/ali/1.0/" specific-use="textmining" content-type="ccbylicense">https://creativecommons.org/licenses/by/4.0/</ali:license_ref><license-p>This is an Open Access article, distributed under the terms of the Creative Commons Attribution licence (<uri xlink:href="https://creativecommons.org/licenses/by/4.0/">https://creativecommons.org/licenses/by/4.0/</uri>), which permits unrestricted re-use, distribution, and reproduction in any medium, provided the original work is properly cited.</license-p></license></permissions><self-uri xlink:title="pdf" xlink:href="S0924933824015402a.pdf"/><abstract><sec id="sec8350"><title>Introduction</title><p>Contrary to classical belief, people affected by this disease are at greater risk of developing organic pathologies.This risk has a very complex&#x000a0;origin: a greater exposure to risk factors and specific socioeconomic conditions, a high prevalence of risk behaviors, the use of antipsychotics, and a potential common genetic background. (Reynolds <italic toggle="yes">et al</italic>.Int. J.Neuropsychopharmacol.2021; 24 854&#x02013;855, <italic toggle="yes">Suvisaari J et al.</italic> Curr Diab Rep. 2016 16). Multiple studies demonstrate that Schizophrenia confers a high endogenous risk of Diabetes. Before patients diagnosed with Schizophrenia start taking antipsychotics (Andreassen OA <italic toggle="yes">et al.</italic> Am J Psychiatry. 2017;174 616-617), they have an approximately 3 times higher risk of developing Diabetes compared to the general population. The risk increases 3.6 times after the initiation of antipsychotic treatment compared to drug naive patients(<italic toggle="yes">Annamalai A et al</italic> World J Diabetes. 2017 390-396)</p></sec><sec id="sec8351"><title>Objectives</title><p>To study the association between Schizophrenia or other Psychotic Disorders and Diabetes Mellitus in a sample of patients diagnosed with Schizophrenia or other Psychotic Disorders.</p></sec><sec id="sec8352"><title>Methods</title><p>This is a Descriptive and Cross-sectional Observational Study. Clinical Histories were reviewed and a personal or telephone interview was established to expand data related to the objectives of the study. The patients were recruited among the patients seen in the specific Severe Mental Disorder consultation who had a diagnosis of schizophrenia or other Psychotic Disorders, according to DSM 5-TR criteria.</p></sec><sec id="sec8353"><title>Results</title><p>From a sample of 93 patients, 24 had Diabetes. The Prevalence of Diabetes in patients with Schizophrenia or other Psychotic Disorders was 25.8%. Of the patients without a diagnosis of Diabetes, 15 of them had values of Glycosylated Hemoglobin (HbA1c) for Prediabetes. Using the Chi-Square Test, statistically significant differences were found between the variable Main Psychiatric Medication and Diabetes. Patients treated with Clozapine, Aripiprazole and Olanzapine had a Prevalence of Diabetes of 40.9%, 33.3% and 28.5%, respectively.</p></sec><sec id="sec8354"><title>Conclusions</title><p>Prevalence of Diabetes in our sample was 3.4 times higher than the 7.51% of the general population in Spain. This presumes a significant importance and impact on the health of these patients. The diabetic patients in our sample were diagnosed with Diabetes years after the diagnosis of the mental illness, which seems to indicate that the causes have to do with lifestyle, dietary habits, weight, and exposure to chronic antipsychotics. Premature death in schizophrenia has several explanations, being of special importance the development of cardiovascular disorders and Diabetes This can be due to many reasons, but it is worth highlighting the metabolic side effects of some antipsychotics and lifestyle. In this sense, it is essential to carefully monitor this group of patients.</p></sec><sec id="sec8355"><title>Disclosure of Interest</title><p>None Declared</p></sec></abstract><counts><page-count count="1"/></counts></article-meta></front></article>